Merck (MRK) secured exclusive global rights to develop and sell China-based Jiangsu Hengrui Pharmaceuticals' heart disease drug in a deal worth up to about $2 billion. The companies said Tuesday ...

Merck & Co. will pay as much as $2 billion for the rights to Jiangsu Hengrui Pharmaceuticals Co.’s experimental heart drug, the US drugmaker’s second recent foray into China for a novel medicine.

Under terms of the deal, Merck will gain global rights to develop, manufacture, and commercialize HRS-5346 for cardiovascular disease, excluding Greater China. News. News. Academy. ... Merck Reaches ...

The agreement comes just three months after Merck said it would be gaining exclusive global rights to Hansoh Pharma’s preclinical GLP-1 candidate, HS-10535, in a deal worth over $2bn. The company will ...

Merck to buy Acceleron for $11 ... “There’s a lot of advances in cardiovascular disease,” Dean Li, president of Merck Research ... The company has rights to market Bayer PAH drug riociguat ...

Merck & Co. will shell out $350 million to acquire NovaCardia, a privately held firm focused on heart disease drugs. NovaCardia's lead product, KW-3902, is a vasodilator in Phase III trials in ...

Merck drug Winrevair is the first in a new class of pulmonary arterial hypertension therapies that address a key signaling pathway behind the disease. The drug comes from Merck’s $11.5 billion ...

Cardiome could make $640 million in milestones. Merck & Co. will pay an initial fee of $60 million to Cardiome Pharma for rights to vernakalant, a drug candidate for atrial fibrillation (AF). […] ...